MISONCT07934121
MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Overall Response Rate(ORR)
Timeframe: up to 24 months
Secondary (6)
Progression-Free Survival(PFS)
During of response*(DoR)
Overall Survival (OS)
CA125 response
Incidence, severity, and duration of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs). (Assessed by the investigator per CTCAE criteria.)
Show 1 moreShow less
Incidence of Grade ≥3 treatment-related adverse events (TRAEs) assessed by the investigator. (Assessed by the investigator per CTCAE criteria.)
Arms and interventions
Mirvetuximab Soravtansine + SuvemcitugExperimental
Patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer will receive mirvetuximab soravtansine combined with suvemcitug. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, death, or other protocol-specified discontinuation criteria.
Drugs: Mirvetuximab Soravtansine, Suvemcitug
Sites
1 site in 1 country
- Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China